Clinical trial
Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia
NCT00021749 · Genta Incorporated, Industry · Completed
Key facts
| NCT number | NCT00021749 |
|---|---|
| Title | Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia |
| Official title | Phase I-II Multicenter Study of Genasense (Bcl-2 Antisense Oligonucleotide) in Patients With Advanced Chronic Lymphocytic Leukemia |
| Lead sponsor | Genta Incorporated, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia, CLL |
| Intervention type | Drug |
| Interventions | Oblimerson sodium, G3139 |
| Enrollment | 40 |
| Start date | Jan 1, 2001 |
| Primary completion | Jan 1, 2003 |
| First posted | Aug 6, 2001 |
| Last update posted | Nov 13, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: